Cloudbreak Therapeutics is a clinical-stage biotechnology company focusing on ocular drug development.
Founded in September 2015 in Irvine, California, USA, Cloudbreak Therapeutics quickly advanced our first drug candidate through lead selection, pre-clinical IND-enabling studies and successful IND submission.
After a successful EOP2 meeting with the FDA in May 2019, Cloudbreak Therapeutics will proceed with Phase III clinical trial to develop a drug candidate which is a disease modifying, first-in-class, and the first drug therapy to treat pterygium.
Cloudbreak Therapeutics operates a capital efficient business model based upon VIC + 505b(2). We repurpose approved systemic drugs for ocular delivery to treat eye diseases and quickly advance drug candidates to complete proof-of-concept (POC) Phase II clinical trials and to out-license global rights for Phase III clinical trials, product registration, and commercialization. Fully embracing the pharmaceutical development ecosystem, we utilize contract research organizations (CRO) for non-clinical, CMC and clinical development to efficiently maximize capital for drug development.
The Cloudbreak Therapeutics management team has over 50 years of combined experience with ocular drug discovery and development. In addition, Cloudbreak Therapeutics is supported by seasoned advisers and consultants.